Investor Relations

StemRIMInvestor Relations

Investor News

May 20, 2025	Timely Disclosure Information	StemRIM Announces Patent Registration (Europe) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders (including Traumatic Cartilage Defect, Osteoarthritis, and Osteochondritis dissecans)
April 9, 2025	Timely Disclosure Information	StemRIM Announces Setting the Record Date for Extraordinary General Meeting of Shareholders Convening and Holding of Extraordinary General Meeting of Shareholders, and Reduction of Capital Stock (Capital Decrease)
April 3, 2025	Timely Disclosure Information	StemRIM Announces Patent Registration (China) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Traumatic articular Cartilage Deficiency Syndrome, Osteoarthritis, and Osteochondritis dissecans
April 2, 2025	Timely Disclosure Information	StemRIM Announces the Interim Analysis Results for the Global Phase 2b Clinical Trial in Patients with Acute Ischemic Stroke

IR Library

Stock Information

Investor Library

This list of analysts was prepared based on material that was available at the time of writing. Therefore, please note that there may be other analysts who have not been included in this list, and that some of the information may not be the latest.
Please note that the analysts have conducted their own analyses of the Company’s performance, businesses, products and technologies, and have developed their own forecasts. These processes do not in any way involve the Company or the management of the Company.
Furthermore, the management of StemRIM does not endorse or concur with the forecasts, opinions and recommendations of these analysts. Thus, we cannot take any responsibility regarding the consistency of such information.
The provision of this list is explicitly for the purpose of introducing analysts of external companies or research-related institutions that have undertaken analyses and forecasts of our corporate performance. This is not for the purpose of soliciting sales of the Company’s stock.
Please note that decisions regarding the purchase of shares are solely up to the investors themselves.